Myxopapillary ependymomas are generally considered benign tumors in adult patients and are seldom observed to undergo anaplastic changes. They can occasionally exhibit elevated MIB-1 labeling indices, recurrence, and seeding of the subarachnoid space. 5 In contrast, recurrence of an MEPN is common in the pediatric population, and more aggressive behavior, including extraneural metastasis, has been reported. 10 Thus, the current classification of pediatric MEPNs belies the biological potential of these tumors. The basis for the higher MEPN recurrence rate in children is unknown. Recently, it was reported that other histological subtypes of EPN that arise throughout the neuraxis exhibit distinct molecular genetic profiles. This observation is based on the differential expression of specific markers including HOXB13, NEFL, PDGFRa, EGFR, EPHB3, AQP1, and JAGGED 1 that represent one or more developmental phenotypes. 23 In light of the divergent clinical behavior of MEPNs in pediatric and adult populations, we decided to characterize the expression of these putative biomarkers in a series of pediatric EPNs and MEPNs to determine whether these proteins correlated with clinical outcome.
Methods
This is a retrospective study of 21 patients with spinal cord EPNs or MEPNs from the Children's Hospital of Philadelphia between 1989 and 2009. All studies were conducted in compliance with local and federal human protection guidelines and institutional review board regulations.
Chart review yielded adequate clinical follow-up data for a total of 19 patients, 8 with a clinical diagnosis of MEPN and 11 with a clinical diagnosis of EPN (Table  1) . Clinical information included patient age, sex, symptoms at presentation, duration of symptoms, tumor location, completeness of resection, disease-free follow-up, radiotherapy, recurrence, complications, and/or residual symptoms.
In 21 cases, formalin-fixed and paraffin-embedded microscopic sections stained with H & E were available for review. Immunohistochemical specimens included 10 EPNs including an anaplastic type and 9 MEPNs. The anaplastic EPN was defined on the basis of increased cellularity and atypia, microvascular proliferation, and roughly 5 mitoses per 10/hpf. A single MEPN and 1 EPN were included in the immunohistochemistry, although follow-up clinical information was not available. In 2 cases of EPN, clinical information and H & E slides to confirm the diagnosis were available, but immunohistochemistry was not performed because paraffin blocks were not available (Table 1) .
Immunohistochemical staining with the following antibodies was performed on a Leica Bond-Max Autostainer using the Bond Polymer Refine Detection System (Leica Microsystems): epithelial membrane antigen (Dako Corp., dilution 1:200), GFAP (Dako, dilution 1:600), Ki 67 antigen (Dako, dilution 1:100), HOXB13 (Santa Cruz Biotechnology, dilution 1:50), AQP1 (Chemicon/Millipore, Corp., dilution1:250), JAGGED 1 (Sigma- . Paraffin sections were cut onto charged glass slides at 5 mm, and dried overnight at 45°C. Deparaffinization, epitope retrieval, and detection were done on a Bond-Max stainer. Detection reagents included a horseradish peroxidaselinked polymer, which works for mouse or rabbit antibodies, and 3,3'-diaminobenzidine chromogen. Sections were counterstained with Gill hematoxylin, washed, dehydrated with graded concentrations of ethanol, cleared in xylene, mounted, and examined microscopically. Appropriate positive and negative control samples were used.
Epithelial membrane antigen and GFAP immunostains were scored by the neuropathologist as positive or negative. All the other stains were scored on a subjective scale from -(minus) to ++ (plus-plus). Between 30% and 100% of cells staining yielded a score of ++. Less than 30% yielded a score of +. The absence of staining was given a designation of minus (-). Tables 2 and 3 contain the clinical data for the MEPN and EPN patients, respectively. For patients with MEPNs the mean age at presentation was 12.8 years (range 10-19 years), whereas that for patients with EPNs was 14.5 years (range 10-22 years). There was a 7:1 male/female predominance in the MEPN series and an approximate 1:1 ratio (5:6 male/female) in the EPN series. In the MEPN cohort, the most common presenting symptom was back pain (n = 6), often worse at night. Leg pain was also a presenting symptom in 3 patients. The mean duration of symptoms was 9.5 months. The most common evidence of recurrence was an abnormal MRI finding, followed by back pain. In the spinal EPN cohort, the most common presenting symptom was neck or back pain (n = 8), arm or leg pain (n = 3), gait disturbance (n = 2), numbness, weakness, torticollis, and urinary symptoms. The mean follow-up period was 79 months (range 4-203 months) for MEPN and 51 months (range 4-150 months) for EPN. The overall survival for both subsets was 100%. However, event-free survival was only 50% for patients with MEPN. The disease-free follow-up duration for the MEPN cohort was 42.4 months, and the mean time to recurrence was 35.75 months in the 4 patients with recurrences. Of note, in all cases in which the MEPN recurred, the patients had undergone gross-total resection on initial surgery. In contrast, there were no tumor recurrences in patients with EPNs. However, 2 patients with EPNs went on to have additional operations. One patient underwent 3 operations for cord untethering after initial resection. The other patient (Case 18) ( Table 1 ) was the only individual with a diagnosis of neurofibromatosis Type 2. She presented with both cervical and thoracic EPNs and underwent initial resection of the symptomatic cervical lesion followed by resection of the thoracic EPN 2 years later when that lesion became symptomatic. This was not counted as a recurrence because both tumors were present on initial presentation.
Results

Clinical Parameters
There were no surgical complications in either group. All patients with MEPNs improved after surgery, with resolution of their symptoms. Most patients with EPNs indicated resolution of their symptoms during the followup period, with 2 exceptions. One patient had residual pain and 1 patient developed kyphosis and residual pain. Figures 1 and 2 illustrate examples of pre-and postsurgical MRI scans for both MEPN and EPN, respectively.
The role of initial radiation treatment after MEPN resection has not been established in the literature. In our series of MEPNs, 5 of 6 patients who underwent grosstotal resection did not receive initial radiation therapy. The remaining patient, who had a metastatic tumor on presentation, underwent proton-beam therapy after gross-total resection of both the primary and metastatic tumor. The 2 patients with subtotal resections elected to undergo craniospinal irradiation (1 unknown dose and the other a 36-cGy dose to the cranial-T9 region, a 50.4-cGy dose to T9-S3, and a 54-cGy dose to S1-3). In 4 of 6 patients, the lesion recurred locally after gross-total resection, and all underwent radiotherapy (2 unknown, 1 a focal 54-cGy dose to the lumbosacral spine, 1 a craniospinal dose of 25.2 cGy, and 1 a 54-cGy boost for a the sacral recurrence) after reresection. These patients experienced a second recurrence that was documented during the follow-up period.
Immunohistochemical Analysis
Our immunohistochemical findings are summarized in Table 4 and Fig. 3 . Both types of tumors were reactive for GFAP, and most demonstrated punctate, cytoplasmic positivity for epithelial membrane antigen, with only a few tumors exhibiting membranous staining. Protein expression of HOXB13 was confined to the nucleus and was present in both MEPNs and EPNs (Fig. 3C and D) . AQUAPORIN1, NEFL, and PDGFRa exhibited cytoplasmic staining in both types of tumors. Approximately half of the samples in both cohorts expressed JAGGED1. Interestingly, EPHB3 demonstrated a tendency to be negative in EPN (Fig. 3E) , which is in keeping with the observation of Taylor et al. 23 of lower EPHB3 protein expression in posterior fossa and spinal EPNs compared with supratentorial EPNs. In contrast, 6 of 9 MEPNs (Fig.  3F ) exhibited positive expression of EPHB3. The small sample size precludes determination of statistical significance for these markers.
Of all initial and recurrent tumors, only 1 MEPN exhibited positive expression for EGFR, whereas all the other MEPNs were negative (Fig. 3H) . Three EPNs, including the Grade III tumor, were positive for EGFR (Fig.  3G) ; however, this was not prognostic of recurrence during our follow-up period. The same observation was true for Ki 67 expression (data not shown). Except for a single anaplastic EPN with a proliferative index that focally reached 10%-15%, all other tumors had a proliferative index below 10%. As with other markers, the proliferative index failed to correlate with the observed biological behavior of either EPNs or MEPNs. Three MEPNs had a proliferative index greater than 5% (range 7%-9%) with varying clinical outcomes. One tumor recurred after 64 months, 1 tumor was a recurrence, and another tumor has not recurred to date.
Discussion
An MEPN designation of WHO Grade I belies its potential for a higher risk of recurrence in children, as evidenced by the greater than 50% recurrence rate. While gross-total resection of MEPNs is considered the current gold-standard treatment, it does not appear to prevent tumor recurrence in children. In fact, all tumors in our series that recurred did so after gross-total resection. Not only do pediatric MEPNs (WHO Grade I) have a higher recurrence rate than their adult counterparts, but they may even recur more frequently than pediatric spinal EPNs (WHO Grade II/III). This conclusion is supported by the results of previous reports on pediatric MEPNs, which reveal a 40% recurrence rate after gross-total resection, 43% after subtotal resection, and 50% after biopsy alone (Table 5) , 1,2,4,6,7,9-14,18-22 whereas the recurrence rate of pediatric spinal EPNs, especially after gross-total resection, is often lower than those observed in the pediatric MEPN population. Benesch et al. 4 reported an 11.7% recurrence rate in 17 patients with Grade II lesions and a 16.7% recurrence rate in 6 patients with Grade III lesions over a combined average follow-up of 4.2 years for their entire series. Of note, there were no recurrences after gross-total resection in the series of Benesch. Lonjon et al. 15 reported 3 tumor recurrences and 2 deaths by disseminated disease (both Grade III tumors) in a series of 20 pediatric patients with intramedullary spinal cord EPNs.
These results reinforce the importance of close longterm follow-up of children with MEPNs, with an emphasis on radiological surveillance to monitor for recurrence. There is also a need for improved adjuvant therapy. While MEPNs exhibit a relatively high rate of recurrence, focal radiotherapy after resection is not the current standard of care. When MEPNs recur, it is usually after a considerable length of time (in our series, the average time to recurrence was 35.75 months), and tumors do not usually exhibit gross dissemination. Recurrence tends to be local and/or limited to the spine. As such, when MEPNs recur, they tend to be easily salvageable with repeat resection and/or focal irradiation. In the case of pediatric patients, the additional 3 years of normal growth likely diminishes the risk of long-term radiation-related morbidity to growing vertebral endplates and scatter to developing thoracic/ abdominal/pelvic organs. As proton-beam radiation therapy becomes more widely available, it may provide an additional therapeutic option.
To identify additional therapeutic options, better knowledge of the biology of MEPNs and spinal EPNs is required. Accordingly, we examined the protein expression of several genes implicated in the pathogenesis 8, 23 in this relatively large cohort of exclusively pediatric spinal cord MEPNs and EPNs. In 2 previous studies, the high expression of multiple Homeobox (HOX) gene family members was reported in spinal EPNs, with HOXB13 being one of the 5 most highly expressed. Conversely, JAGGED 1 and EPHB3 appear to be signature genes of supratentorial EPNs, where the EPHB-EPHRIN cell-signal system plays a key role in maintaining normal neural stem cells in the cerebral subventricular zone. 8 Aquaporin 1 is another protein of interest expressed in posterior fossa EPNs and less in the spinal EPNs. 23 In addition, we selected NEFL and PDGFRa, which were shown by Barton et al. 3 to be highly expressed in MEPNs. We examined EGFR because of the possible prognostic value of this stain in adults with MEPNs. Also, a recent abstract reported EGFR as a possible predictor of relapse in a pediatric MEPN series.
24
Our immunohistochemical analysis demonstrated that HOXB13 is expressed in both MEPNs and spinal EPNs, confirming the data of Taylor and colleagues. 23 Surprisingly, Barton and associates 3 reported that only 1 of 8 spinal EPNs was positive for HOXB13. The different results most likely reflect the fact that only 1 of their 8 EPNs was in a pediatric patient. In fact, none of our tumors was strongly positive for JAGGED 1, considered a signature protein for supratentorial rather than spinal EPNs. However, we did not observe any differences between MEPNs and spinal EPNs, with weak positivity seen in only half of each tumor type. In our series, both MEPNs and spinal EPNs expressed AQP1. Taylor and coworkers 23 reported a significantly lower expression of AQP1 in spinal EPNs than posterior fossa tumors. However, the expression is not negative in spinal EPNs, but is merely 30% versus 75%-80% in the latter. Different experimental conditions may account for the variance between our results and those of the Taylor group. With positive PDGFRa staining seen in the majority of both tumor types, our findings confirm previous reports, which further support the potential of PDGFRa as a therapeutic target. 3 Interestingly, only 2 (20%) of 10 positive spinal EPNs compared with 6 (67%) of 9 MEPNs expressed EPBH-3 in our series (Table 4) .
Taylor and coworkers 23 have described a higher expression of EPHB-3 in supratentorial EPNs than in posterior fossa or spinal tumors. The question arises of whether the potentially aggressive biological behavior of MEPNs in children may be related to the higher expression of a member of the EPHB-EPHRIN family, similar to their supratentorial counterpart. This is an intriguing hypothesis that would need more cases and further investigation to be confirmed.
In our cohort, we found no correlation between tumor recurrence and positive EGFR staining. This finding differs from reports in intracranial EPNs, 17 in which EGFR overexpression appears to be an independent predictor of poor prognosis. Our results also differ from a recent abstract that reported that EGFR expression was a likely predictor of relapse in 4 of 7 cases of pediatric MEPNs. 24 Although our study represents the second-largest cohort to date of pediatric MEPNs and spinal cord EPNs 4 and, more importantly, the first attempt to link clinical outcome to the expression of signature proteins in children, the overall sample size was too small to draw definitive conclusions regarding tumor biology and therapy.
Conclusions
In this large series of pediatric spinal EPNs, MEPNs showed a high rate of recurrence (50%) that was independent of completeness of resection. In addition, there was a trend toward higher expression of EPBH-3 in MEPNs compared with other pediatric spinal EPNs. We observed no correlation between EGFR, Ki 67, or other markers of EPN and the clinical behavior of these tumors.
Based on these results, we conclude that the WHO Grade I assigned to MEPNs, at least in children, underestimates the high risk of recurrence. To develop more effective therapeutic approaches for pediatric MEPNs, further investigation of the prognostic and recurrence risks is warranted. Finally, there is a need for heightened clinical awareness and close monitoring of patients with spinal cord EPNs. 
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